Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genomic Health, Inc. stock logo
GHDX
Genomic Health
$63.44
$64.79
$50.77
$90.18
$2.38B0.91.05 million shsN/A
Natera, Inc. stock logo
NTRA
Natera
$161.50
0.0%
$160.34
$92.14
$183.00
$22.09B1.731.43 million shs468,868 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
RadNet, Inc. stock logo
RDNT
RadNet
$56.16
+0.9%
$56.64
$45.00
$93.65
$4.22B1.41684,265 shs251,969 shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$27.51
-0.3%
$28.10
$19.73
$47.32
$2.15B2.07918,675 shs445,469 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genomic Health, Inc. stock logo
GHDX
Genomic Health
0.00%0.00%0.00%0.00%0.00%
Natera, Inc. stock logo
NTRA
Natera
0.00%-3.85%-2.42%+20.64%+44.66%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-57.14%
RadNet, Inc. stock logo
RDNT
RadNet
0.00%-1.68%-3.29%+15.32%-5.23%
Veracyte, Inc. stock logo
VCYT
Veracyte
0.00%+0.47%+1.96%-4.97%+28.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genomic Health, Inc. stock logo
GHDX
Genomic Health
N/AN/AN/AN/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
2.1396 of 5 stars
2.52.00.00.03.42.50.6
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
3.6763 of 5 stars
2.82.00.04.62.12.50.0
Veracyte, Inc. stock logo
VCYT
Veracyte
3.6112 of 5 stars
3.41.00.04.32.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genomic Health, Inc. stock logo
GHDX
Genomic Health
0.00
N/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.6314.32% Upside
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
3.50
Strong Buy$69.6023.93% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9048.67% Upside

Current Analyst Ratings Breakdown

Latest GHDX, NTRA, NVTA, VCYT, and RDNT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$69.00
6/12/2025
RadNet, Inc. stock logo
RDNT
RadNet
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$49.00 ➝ $42.00
5/8/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$51.00 ➝ $41.00
4/11/2025
RadNet, Inc. stock logo
RDNT
RadNet
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$88.00 ➝ $74.00
4/10/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$200.00 ➝ $160.00
4/9/2025
Veracyte, Inc. stock logo
VCYT
Veracyte
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$45.00 ➝ $37.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genomic Health, Inc. stock logo
GHDX
Genomic Health
$394.11M6.05$1.45 per share43.76$7.48 per share8.48
Natera, Inc. stock logo
NTRA
Natera
$1.70B13.00N/AN/A$9.05 per share17.85
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
RadNet, Inc. stock logo
RDNT
RadNet
$1.83B2.30$3.48 per share16.14$15.31 per share3.67
Veracyte, Inc. stock logo
VCYT
Veracyte
$463.39M4.65$1.04 per share26.53$15.17 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genomic Health, Inc. stock logo
GHDX
Genomic Health
$25.68M$1.0560.4236.88N/A12.81%19.62%14.89%N/A
Natera, Inc. stock logo
NTRA
Natera
-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
RadNet, Inc. stock logo
RDNT
RadNet
$2.79M-$0.43N/A105.96N/A-1.73%1.41%0.48%8/6/2025 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.4167.1038.21N/A7.13%6.14%5.60%8/5/2025 (Estimated)

Latest GHDX, NTRA, NVTA, VCYT, and RDNT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genomic Health, Inc. stock logo
GHDX
Genomic Health
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
RadNet, Inc. stock logo
RDNT
RadNet
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genomic Health, Inc. stock logo
GHDX
Genomic Health
0.15
5.96
5.96
Natera, Inc. stock logo
NTRA
Natera
N/A
3.87
3.74
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
RadNet, Inc. stock logo
RDNT
RadNet
0.87
2.01
2.01
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.10
4.78

Institutional Ownership

CompanyInstitutional Ownership
Genomic Health, Inc. stock logo
GHDX
Genomic Health
93.87%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Invitae Co. stock logo
NVTA
Invitae
61.28%
RadNet, Inc. stock logo
RDNT
RadNet
77.90%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Genomic Health, Inc. stock logo
GHDX
Genomic Health
31.30%
Natera, Inc. stock logo
NTRA
Natera
7.60%
Invitae Co. stock logo
NVTA
Invitae
0.74%
RadNet, Inc. stock logo
RDNT
RadNet
5.60%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genomic Health, Inc. stock logo
GHDX
Genomic Health
82937.59 millionN/AOptionable
Natera, Inc. stock logo
NTRA
Natera
4,434136.55 million126.17 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
RadNet, Inc. stock logo
RDNT
RadNet
11,02175.03 million70.83 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.32 million77.22 millionOptionable

Recent News About These Companies

Veracyte, Inc. (VCYT) - Yahoo Finance
Veracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Genomic Health stock logo

Genomic Health NASDAQ:GHDX

Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.

Natera stock logo

Natera NASDAQ:NTRA

$161.50 -0.07 (-0.04%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$161.50 0.00 (0.00%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

RadNet stock logo

RadNet NASDAQ:RDNT

$56.16 +0.51 (+0.92%)
Closing price 07/3/2025 02:28 PM Eastern
Extended Trading
$56.16 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$27.51 -0.07 (-0.25%)
Closing price 07/3/2025 03:36 PM Eastern
Extended Trading
$27.67 +0.16 (+0.58%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.